Drug Profile
Berotralstat - BioCryst Pharmaceuticals
Alternative Names: PrORLADEYO; BCX-7353; Berotralstatum; ORLADEYOLatest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator BioCryst Pharmaceuticals
- Class Amides; Fluorinated hydrocarbons; Pyrazoles; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hereditary angioedema
Most Recent Events
- 17 Apr 2024 Registered for Hereditary angioedema (In adolescents, In adults, In the elderly, Prevention) in Brazil (PO)
- 17 Apr 2024 Biocryst Pharmaceuticals plans to launch berotalstst in Brazil and across Latin America
- 21 Mar 2024 BioCryst Pharmaceuticals plans to submit supplemental New Drug Application (sNDA) for the potential expanded use of Berotralstat in children in the US in the year 2025